51 without the letrozole study; CI, 1
Feb 2, 2022 · Many studies have compared outcomes in post-menopausal women treated with AI vs
Jul 23, 2015 · Aromatase inhibitors reduce recurrence rates by about 30% (proportionately) compared with tamoxifen while treatments differ, but not thereafter
Jan 6, 2004 · Comparative data concerning the efficacy, toxicity, tolerability and cost of AI vs tamoxifen continues to evolve with over 40 000 women slated to be involved in clinical trials
tamoxifen in MBC 15–17
Jun 20, 2014 · LBA1 Background: Adjuvant endocrine therapy with AI vs T improves outcomes in postmenopausal HR+ BC
Methods: We undertook
[ show] For post-menopausal women with a higher-than-average risk of breast cancer who are considering taking medicine to lower their risk, drugs called
1016/j
Clinical trials have reported conflicting results as to whether Aromatase inhibitors (AIs) as first-line hormonal therapy improve
AI users suffered more frequently from musculoskeletal complaints, and
Joint and muscle pain
We performed a meta-analysis comparing primary and secondary endpoints of AIs to tamoxifen as
Finally, some women may switch to an aromatase inhibitor after 2 or 3 years of tamoxifen, for a total of 5 or more years of hormone therapy
These treatments are administered in a variety of adjuvant regimens, including tamoxifen for 10 years, tamoxifen for up to 5 years followed by an aromatase inhibitor for 5 years, or an initial For women with early breast cancer, treatment with an aromatase inhibitor (alone or after tamoxifen) lowers the risk of [1]: Breast cancer recurrence (a return of breast cancer) Breast cancer in the opposite breast
5% for tamoxifen vs 14
Premenopausal women can also opt to have The 8-year rate of overall survival was 91
34; 95% CI, 1
With tamoxifen, it's more erratic
Aromatase inhibitors only work in post-menopausal women, but tamoxifen and raloxifene work in both pre- and post-menopausal women
Some younger, premenopausal women at high risk of breast cancer recurrence may benefit from treatment with ovarian suppression plus tamoxifen or an aromatase inhibitor [8,90,97,127-129]
Benefits of AI plus OFS versus tamoxifen alone were greater, with 3
It's often used to reduce the risk of cancer recurrence after treatment for early-stage breast cancer
Clinical practice guidelines recommend the use of an AI or TAM